Ephedra & stroke
This article was originally published in The Tan Sheet
Executive Summary
"Association between the use of ephedra-containing products and increased risk for hemorrhagic stroke" was not demonstrated in Hemorrhagic Stroke Project, L.B. Morgenstern, MD, University of Texas at Houston, et al., report in the January issue of Neurology. However, researchers note "analysis by dose suggests there may be an association with use of more than 32 mg/d" ephedra. Morgenstern et al. analyzed 702 subjects who enrolled between December 1994 and July 1999 in the HSP, which was designed to investigate association between phenylpropanolamine and hemorrhagic stroke risk. HSP findings eventually prompted FDA to request PPA marketers pull the ingredient off the market...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.